Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 301 participants.

Also called NCT03219320

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose supportive care
Phase
Phase 2
Enrolled
  • 301 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03219320
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03219320. Randomized; triple masking; primary purpose supportive care. Start 2017-06-27 (actual); primary completion 2018-11-02 (actual). Results posted on 2020-06-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Acronym
DPN
Condition
Diabetic Peripheral Neuropathy
Intervention (Drug)
NYX-2925
Intervention (Drug)
Placebo
Lead sponsor
Aptinyx (class: industry)
Collaborator
Syneos Health (class: other)

Record details

Record id
cardio:ct-nct03219320
Content hash
f2c9ed338911f79321a32144998efceed2113ac2be23f1a678f738cf016b67d1